<DOC>
	<DOCNO>NCT00170898</DOCNO>
	<brief_summary>This study design develop understanding risk-benefit use lumiracoxib patient acute musculoskeletal pain due uncomplicated soft tissue injury .</brief_summary>
	<brief_title>Safety Efficacy Lumiracoxib Versus Naproxen Acute Musculoskeletal Pain</brief_title>
	<detailed_description />
	<mesh_term>Musculoskeletal Pain</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Inclusion Criteria Patients acute musculoskeletal pain follow uncomplicated soft tissue injury ( within last 72 hour ) expect selflimiting , require shortterm treatment NSAID . Patients ’ acute musculoskeletal pain baseline must ≥ 50 mm 0 – 100 mm Visual Analogue Scale . Patients may take analgesic therapy follow injury . However , baseline pain intensity assessment take : ( ) 4 hour last dose ≤ 400 mg ibuprofen , ≤ 1000 mg paracetamol , ≤ 600 mg aspirin ≤ 2 tablet overthecounter analgesic aspirinbased paracetamolbased combination medication ( ii ) 8 hour last dose &gt; 400 mg ibuprofen ≤ 50 mg diclofenac Exclusion Criteria Patients whose pain due acute exacerbation chronic condition e.g . osteoarthritis , rheumatoid arthritis , systemic lupus erythematosus . Patients take nonsteroidal antiinflammatory drug previous 24 hour ( aspirin , ibuprofen , diclofenac , describe ) . Other protocoldefined inclusion/ exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Musculoskeletal pain</keyword>
	<keyword>cyclooxygenase-2 inhibitor</keyword>
	<keyword>lumiracoxib</keyword>
	<keyword>naproxen</keyword>
</DOC>